Clinical Trial Update: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating ianalumab versus placebo (with standard of care) in active lupus nephritis, focusing on safety, efficacy and tolerabi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• Ianalumab (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lupus Nephritis | Phase 3 | Status: RECRUITING